Press Release
« Back
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual Meeting
Nov 03, 2016
"We are looking forward to an exciting ASH conference as we continue to present data on the differentiation between TGR-1202 and the first generation PI3K delta inhibitors. With three oral presentations and three poster presentations it is clear the strength of TGR-1202, and our overall UNITY program, is starting to be noticed by leaders in the treatment of B-cell malignancies. We have seen scientific and clinical interest in our programs continue to grow, and notably all three of the oral presentations at this coming ASH meeting resulted from independent investigator driven interest in working with TGR-1202. We look forward to sharing this data at the upcoming meeting and expanding on our investigator initiated collaborations while we continue to drive our registration-directed trials toward pivotal data in 2017, potentially leading to our first approval in 2018," stated
Presentations at the ASH 2016 meeting include the following:
Oral Presentations:
- Title: Silencing c-Myc Translation as a Therapeutic Strategy through
Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies- Abstract Number: 291
Oral Session : 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Cell Signaling- Date and Time:
Sunday, December 4, 2016 ;7:30 AM - 9:00 AM PT - Presentation Time:
8:00 AM PT - Location:
San Diego Convention Center , Room 5AB - Presenter:
Changchun (George) Deng , MD, PhD,Columbia University ,New York, NY
- Title: TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
- Abstract Number: 641
Oral Session : 642. CLL: Therapy, excluding Transplantation: Targeted Therapy: Novel Agents and Combinations- Date and Time:
Monday, December 5, 2016 ;7:00 AM - 8:30 AM PT - Presentation Time:
8:00 AM PT - Location:
San Diego Convention Center , Room 5AB - Presenter:
Matthew S. Davids , MD,Dana Farber Cancer Institute ,Boston, MA
- Title: Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor
TGR-1202 in Myelofibrosis
- Abstract Number: 1125
Oral Session : 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with JAK Inhibitors- Date and Time:
Monday, December 5, 2016 ;4:30 PM - 6:00 PM PT - Presentation Time:
5:00 PM PT - Location:
Marriott Marquis San Diego Marina , Pacific Ballroom Salons 15-17 - Presenter:
Tamara Kay Moyo , MD, PhD,Vanderbilt-Ingram Cancer Center ,Nashville, TN
Posters Presentations:
- Title: Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202
- Abstract Number: 3236
- Session: 642. CLL: Therapy, excluding Transplantation: Poster II
- Date and Time:
Sunday, December 4, 2016 6:00 PM - 8:00 PM PT - Location:
San Diego Convention Center , Hall GH - Presenter:
Kamira K. Maharaj , BS,Moffit Cancer Center ,Tampa, FL
- Title:
Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma
- Abstract Number: 4197
- Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
- Date and Time:
Monday, December 5, 2016 ;6:00 PM-8:00 PM PT - Location:
San Diego Convention Center , Hall GH - Presenter:
Matthew A. Lunning , DO,University of Nebraska Medical Center ,Omaha, NE
- Title: A Phase I Trial of TGR-1202, a
Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma- Abstract Number: 4146
- Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
- Date and Time:
Monday, December 5, 2016 ;6:00 PM-8:00 PM PT - Location:
San Diego Convention Center , Hall GH - Presenter:
Rod Ramchandren , MD,Karmanos Cancer Center ,Detroit, MI
A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org. Following each presentation, the data presented will be available on the Publications page of the Company's website at www.tgtherapeutics.com.
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202,
the IRAK4 inhibitor program, the
TGTX - G
CONTACT:Source:Jenna Bosco Vice President, Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media